A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib-Reference-Cited by-同舟云学术

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Published:2019-12-19 Issue:25 Volume:134 Page:2271-2280
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Manwani Richa¹,Cohen Oliver¹,Sharpley Faye¹,Mahmood Shameem¹,Sachchithanantham Sajitha¹,Foard Darren¹,Lachmann Helen J.¹,Quarta Cristina¹,Fontana Marianna¹,Gillmore Julian D.¹,Whelan Carol¹,Hawkins Philip N.¹,Wechalekar Ashutosh D.¹

Affiliation:

1. National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom

Abstract

This article reports the largest series of patients with systemic AL amyloidosis to date treated with first-line bortezomib. With relatively mature follow-up, the data indicate the importance of a stringent dFLC response (difference in involved and uninvolved light chains) as a predictor of prolonged response.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/25/2271/1549293/bloodbld2019000834.pdf

Reference24 articles.

1. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis;Kastritis;J Clin Oncol,2010

2. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis;Mikhael;Blood,2012

3. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival;Venner;Blood,2012

4. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis;Palladini;Blood,2015

5. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III);Jaccard;Haematologica,2014

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Periorbital purpura can be the only initial symptom of primary light chain amyloidosis: A case report;World Journal of Clinical Cases;2024-09-16

2. Changes in the clinical features, treatments, and outcomes of patients with systemic light chain (AL) amyloidosis in Western China, 2010–2022: A multicenter, retrospective, real-world study;Chinese Medical Journal;2024-09-12

3. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system;American Journal of Hematology;2024-08-29

4. Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?;Expert Review of Hematology;2024-08-20

5. Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population;Blood;2024-08-15